606093-58-7

Basic information

• Product Name: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate
• Synonyms: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate;Methyl 4-amino-2-anilino-3-fluoro-5-nitrobenzoate;Benzoicacid, 4-aMino-3-fluoro-5-nitro-2-(phenylaMino)-, Methyl ester;4-Amino-3-fluoro-5-nitro-2-phenylaminobenzoic acid methyl ester
• CAS NO: 606093-58-7
• Molecular Formula: C₁₄H₁₂FN₃O₄
• Molecular Weight: 305.264
• Mol File: 606093-58-7.mol

Chemical Properties

• Boiling Point: 475.2°C at 760 mmHg
• Flash Point: 241.2°C
• Appearance: /
• Density: 1.441g/cm³
• Vapor Pressure: 3.39E-09mmHg at 25°C
• Refractive Index: 1.66
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: -4.00±0.25(Predicted)
• CAS DataBase Reference: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate(606093-58-7)
• EPA Substance Registry System: Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate(606093-58-7)

Safety Data

• Hazardous Substances Data: 606093-58-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate is used as an intermediate in the synthesis of various pharmaceutical drugs. Its specific chemical properties make it a valuable component in the creation of new medications, potentially contributing to advancements in healthcare and treatment options.
Used in Drug Development and Research:
In the realm of drug development and research, Methyl 4-Amino-3-Fluoro-5-Nitro-2-(Phenylamino)Benzoate serves as a key substance for exploring new chemical entities and enhancing existing drug formulations. Its unique structure and reactivity can be leveraged to improve the efficacy, safety, and delivery of pharmaceutical products.

InChI:InChI=1/C14H12FN3O4/c1-22-14(19)9-7-10(18(20)21)12(16)11(15)13(9)17-8-5-3-2-4-6-8/h2-7,17H,16H2,1H3

Upstream product

• 284030-58-6 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 
• 284030-57-5 4-amino-2,3-difluoro-5-nitro-benzoic acid 
• 197520-71-1 2,3,4-trifluoro-5-nitro-benzoic acid 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 
• 62-53-3 aniline 

Downstream Products

• 606093-59-8 7-Fluoro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 
• 606144-42-7 4,5-diamino-3-fluoro-2-phenylamino-benzoic acid methyl ester 
• 1000340-06-6 methyl 5-[(4-bromophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 606144-02-9 methyl 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylate 
• 606144-04-1 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid 
• 606144-05-2 5-[(4-bromo-2-chlorophenyl)amino]-N-[2-(ethenyloxy)ethoxy]-4-fluoro-1-methyl-1H-benzimidazole-6-carboxamide 
• 606143-52-6 selumetinib 

Relevant articles and documents

Substituted benzimidazole compound and composition with compound

The invention provides a substituted benzimidazole compound and a composition with the compound. The substituted benzimidazole compound is a compound of formula (I) as shown in the specification, or apharmaceutically acceptable salt, prodrug, aquo-complex or solvent compound, polycrystalline type compound, stereisomer or isotope variant of the compound. The compound provided by the invention canbe adopted to treat and/or prevent related diseases caused by MEK (Methyl Ethyl Ketone), such as excessive proliferative diseases, pancreatitis, kidney illness, blastocyte cell transplantation and angiogenesis or angiopoiesis related diseases.

NOVEL HYDROGEN SULFATE SALT

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, t, R1, R2, R7, R9, R10, R11 and R12 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.